REGENEREX PHARMA, INC.
CIK 1357878fmd_1NHAZCFZ4B5RNG8GZRS3F8EM11Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Dec 01, 2008 to Dec 31, 2025, 59 periods
| Line item | FY2014 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | 0 | 0 | – | – | – | – |
| Cost of revenue | – | – | – | – | 0 | 0 | – | – | – | – |
| Commissions and fees | 0 | – | – | – | – | – | – | – | – | – |
| Gross profit | – | – | – | – | 0 | (0) | – | – | – | – |
| Research and development | – | – | – | – | – | – | – | – | 2 | 1 |
| Selling, general and administrative | – | – | – | – | 0 | 0 | – | – | 1 | 1 |
| Total operating expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 2 |
| Operating income | – | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (3) | (2) |
| Interest expense | 0 | – | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income (expense) | – | – | – | (0) | (0) | (0) | (0) | (0) | (0) | (1) |
| Income before taxes | (0) | – | – | – | – | – | – | – | – | – |
| Income tax expense | – | – | – | – | – | – | – | – | – | (0) |
| Net income from continuing operations | – | – | – | – | – | (0) | (0) | (0) | – | – |
| Net income | 1 | (0) | (0) | (0) | 0 | (0) | (0) | (0) | (4) | (3) |